Prophylactic Loperamide Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer – OncLive

Prophylactic Loperamide Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer
OncLive
Grade 3 diarrhea occurred in 16% of patients treated with neratinib and prophylactic loperamide, representing a significant reduction compared with phase III findings from the ExteNET trial, according to an open-label study presented by Puma

diarrhea – Google News